Inherited cancer syndromes in children and young adults

Journal of Pediatric Hematology/Oncology

Volumn 32, Issue 3, 2010, Pages 195-228

  D'Orazio, John A ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Familial cancer; Genetics; Oncology; Pediatric; Predisposition; Syndrome; Tumor

Indexed keywords

RECQ HELICASE;

ADULT; ARTICLE; ATAXIA TELANGIECTASIA; AUTOSOMAL DOMINANT DISORDER; AUTOSOMAL RECESSIVE DISORDER; BASAL CELL NEVUS SYNDROME; BECKWITH WIEDEMANN SYNDROME; BREAST CANCER; CANCER RISK; CHILD; CHROMOSOME ABERRATION; CLINICAL FEATURE; COCKAYNE SYNDROME; COLON CANCER; DENYS DRASH SYNDROME; DOWN SYNDROME; FAMILIAL CANCER; FAMILY HISTORY; FANCONI ANEMIA; FRASIER SYNDROME; GENE MUTATION; GENETIC PREDISPOSITION; GENETIC SCREENING; HUMAN; JUVENILE POLYPOSIS SYNDROME; KLINEFELTER SYNDROME; MULTIPLE CANCER; MULTIPLE ENDOCRINE NEOPLASIA; NEPHROBLASTOMA; NEUROFIBROMATOSIS; ONCOGENE; OVARY CANCER; PHAKOMATOSIS; PHENOTYPIC VARIATION; POLYPOSIS; PRESCHOOL CHILD; PRIORITY JOURNAL; RETINOBLASTOMA; RHABDOID TUMOR; SCHOOL CHILD; SEX CHROMOSOME ABERRATION; SIMPSON GOLABI BEHMEL SYNDROME; TRICHOTHIODYSTROPHY; TUBEROUS SCLEROSIS; VON HIPPEL LINDAU DISEASE; WAGR SYNDROME; XERODERMA PIGMENTOSUM;

ADULT; CHILD; GENETIC PREDISPOSITION TO DISEASE; HUMANS; NEOPLASTIC SYNDROMES, HEREDITARY; YOUNG ADULT;

EID: 77951082073     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e3181ced34c     Document Type: Article

References (460)

1. Pakakasama S, Tomlinson GE. Genetic predisposition and screening in pediatric cancer. Pediatr Clin North Am. 2002;49: 1393-1413.
2. Greco KE, Mahon S. Common hereditary cancer syndromes. Semin Oncol Nurs. 2004;20:164-177.
3. Plon SE, Nathanson K. Inherited susceptibility for pediatric cancer. Cancer J. 2005;11:255-267.
4. Strahm B, Malkin D. Hereditary cancer predisposition in children: genetic basis and clinical implications. Int J Cancer. 2006;119:2001-2006.
5. Field M, Shanley S, Kirk J. Inherited cancer susceptibility syndromes in paediatric practice. J Paediatr Child Health. 2007;43:219-229. (Pubitemid 46570079)
6. Rao A, Rothman J, Nichols KE. Genetic testing and tumor surveillance for children with cancer predisposition syndromes. Curr Opin Pediatr. 2008;20:1-7.
7. Down JLH. Observations on an ethnic classification of idiots. London Hosp Rep. 1866;3:259-262.
8. Jacobs EM, Baikie AG, Court Brown WM, et al. The somatic chromosomes in mongolism. Lancet. 1959;1:710.
9. Lejeune J. Le mongolisme. Premier example d'aberration autosomique humaine. Ann Genet. 1959;1:41-49.
10. Blank CE, Lord PM, Casey MD, et al. Chromosomes mosaicism in a mongol born to a young mother. Cytogenetics. 1963;85:76-85.
11. Richards BW, Stewart A, Sylvester PE. Reciprocal translocation and mosaicism in a mongol. J Ment Defic Res. 1965;9: 118-124.
12. Eber LM, Goodman RM. The importance of chromosome analysis in Down's syndrome. A case report of a 21-21 translocation. Ohio State Med J. 1966;62:40-43.
13. Roizen NJ, Patterson D. Down's syndrome. Lancet. 2003; 361:1281-1289.
14. Stark CR, Mantel N. Effects of maternal age and birth order on the risk of mongolism and leukemia. J Natl Cancer Inst. 1966;37:687-698.
15. Brewster HF, Cannon HE. Acute lymphatic leukemia: report of a case in eleventh month mongolian idiot. New Orleans Med Surg J. 1930;82:872-873.
16. Krivit W, Good RA. Simultaneous occurrence of mongolism and leukemia; report of a nationwide survey. AMA J Dis Child. 1957;94:289-293.
17. Hasle H, Clemmensen IH, Mikkelsen M. Risks of leukaemia and solid tumours in individuals with Down's syndrome. Lancet. 2000;355:165-169.
18. Rabin KR, Whitlock JA. Malignancy in Children with Trisomy 21. Oncologist. 2009;14:164-173.
19. Zipursky A, Peeters M, Poon A. Megakaryoblastic leukemia and Down's syndrome-a review. Prog Clin Biol Res. 1987; 246:33-56.
20. Homans AC, Verissimo AM, Vlacha V. Transient abnormal myelopoiesis of infancy associated with trisomy 21. Am J Pediatr Hematol Oncol. 1993;15:392-399.
21. Luna-Fineman S, Shannon KM, Atwater SK, et al. Myelodysplastic and myeloproliferative disorders of childhood: a study of 167 patients. Blood. 1999;93:459-466.
22. Al-Kasim F, Doyle JJ, Massey GV, et al. Incidence and treatment of potentially lethal diseases in transient leukemia of Down syndrome: Pediatric Oncology Group Study. J Pediatr Hematol Oncol. 2002;24:9-13.
23. Massey GV, Zipursky A, Chang MN, et al. A prospective study of the natural history of transient leukemia (TL) in neonates with Down syndrome (DS): Children's Oncology Group (COG) study POG-9481. Blood. 2006;107:4606-4613.
24. Look AT. A leukemogenic twist for GATA1. Nat Genet. 2002;32:83-84.
25. Wechsler J, Greene M, McDevitt MA, et al. Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nat Genet. 2002;32:148-152.
26. Gurbuxani S, Vyas P, Crispino JD. Recent insights into the mechanisms of myeloid leukemogenesis in Down syndrome. Blood. 2004;103:399-406.
27. Bercovich D, Ganmore I, Scott LM, et al. Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome. Lancet. 2008;372:1484-1492.
28. Kearney L, Gonzalez De Castro D, Yeung J, et al. Specific JAK2 mutation (JAK2R683) and multiple gene deletions in Down syndrome acute lymphoblastic leukemia. Blood. 2009; 113:646-648.
29. Krajinovic M, Lamothe S, Labuda D, et al. Role of MTHFR genetic polymorphisms in the susceptibility to childhood acute lymphoblastic leukemia. Blood. 2004;103:252-257. (Pubitemid 38029946)
30. Gamis AS. Acute myeloid leukemia and Down syndrome evolution of modern therapy-state of the art review. Pediatr Blood Cancer. 2005;44:13-20.
31. Linabery AM, Blair CK, Gamis AS, et al. Congenital abnormalities and acute leukemia among children with Down syndrome: a Children's Oncology Group study. Cancer Epidemiol Biomarkers Prev. 2008;17:2572-2577.
32. Sussan TE, Yang A, Li F, et al. Trisomy represses Apc(Min)- mediated tumours in mouse models of Down's syndrome. Nature. 2008;451:73-75.
33. Lee M, Hyun D, Jenner P, et al. Effect of overexpression of wild-type and mutant Cu/Zn-superoxide dismutases on oxidative damage and antioxidant defences: relevance to Down's syndrome and familial amyotrophic lateral sclerosis. J Neurochem. 2001;76:957-965.
34. Zorick TS, Mustacchi Z, Bando SY, et al. High serum endostatin levels in Down syndrome: implications for improved treatment and prevention of solid tumours. Eur J Hum Genet. 2001;9:811-814.
35. Jacobs PA, Strong JA. A case of human intersexuality having a possible XXY sex-determining mechanism. Nature. 1959; 183:302-303.
36. Chaussain JL, Lemerle J, Roger M, et al. Klinefelter syndrome, tumor, and sexual precocity. J Pediatr. 1980;97: 607-609.
37. Bussey KJ, Lawce HJ, Olson SB, et al. Chromosome abnormalities of eighty-one pediatric germ cell tumors: sex-, age-, site-, and histopathology-related differences-a Children's Cancer Group study. Genes Chromosomes Cancer. 1999;25:134-146.
38. Swerdlow AJ, Schoemaker MJ, Higgins CD, et al. Cancer incidence and mortality in men with Klinefelter syndrome: a cohort study. J Natl Cancer Inst. 2005;97:1204-1210.
39. Bauer DD, Erickson RL. Male breast cancer; Klinefelter syndrome with prostatic, adrenal and mammary tumors. Northwest Med. 1955;54:472-476.
40. Sandison AT. Male breast cancer in klinefelter's syndrome. Br Med J. 1965;1:521-522.
41. Casalone R, Righi R, Granata P, et al. Cerebral germ cell tumor and XXY karyotype. Cancer Genet Cytogenet. 1994;74: 25-29.
42. Nichols CR, Heerema NA, Palmer C, et al. Klinefelter's syndrome associated with mediastinal germ cell neoplasms. J Clin Oncol. 1987;5:1290-1294.
43. Hultborn R, Hanson C, Kopf I, et al. Prevalence of Klinefelter's syndrome in male breast cancer patients. Anticancer Res. 1997;17:4293-4297.
44. Hwang JJ, Dharmawardana PG, Uchio EM, et al. Prostate cancer in Klinefelter syndrome during hormonal replacement therapy. Urology. 2003;62:941.
45. Yano T, Yuzurio S, Kimura K, et al. Ph-positive acute lymphocytic leukemia in a man with Klinefelter syndrome. Cancer Genet Cytogenet. 2000;118:83-84.
46. Yenamandra A, Zhou X, Trinchitella L, et al. Renal cell carcinoma with X;1 translocation in a child with Klinefelter syndrome. Am J Med Genet. 1998;77:281-284.
47. Horsman DE, Pantzar JT, Dill FJ, et al. Klinefelter's syndrome and acute leukemia. Cancer Genet Cytogenet. 1987;26:375-376.
48. Lohmann DR, Gallie BL. Retinoblastoma: revisiting the model prototype of inherited cancer. Am J Med Genet C Semin Med Genet. 2004;129C:23-28.
49. Knudson AG. Cancer genetics. Am J Med Genet. 2002;111: 96-102.
50. Knudson AG Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A. 1971;68:820-823.
51. Brichard B, Heusterspreute M, De Potter P, et al. Unilateral retinoblastoma, lack of familial history and older age does not exclude germline RB1 gene mutation. Eur J Cancer. 2006;42: 65-72.
52. Abramson DH, Beaverson K, Sangani P, et al. Screening for retinoblastoma: presenting signs as prognosticators of patient and ocular survival. Pediatrics. 2003;112:1248-1255.
53. Antoneli CB, Ribeiro Kde C, Sakamoto LH, et al. Trilateral retinoblastoma. Pediatr Blood Cancer. 2007;48:306-310.
54. Aerts I, Lumbroso-Le Rouic L, Gauthier-Villars M, et al. Retinoblastoma. Orphanet J Rare Dis. 2006;1:31.
55. De Aguirre Neto JC, Antoneli CB, Ribeiro KB, et al. Retinoblastoma in children older than 5 years of age. Pediatr Blood Cancer. 2007;48:292-295.
56. Newton WA Jr, Meadows AT, Shimada H, et al. Bone sarcomas as second malignant neoplasms following childhood cancer. Cancer. 1991;67:193-201.
57. Krengli M, Hug EB, Adams JA, et al. Proton radiation therapy for retinoblastoma: comparison of various intraocular tumor locations and beam arrangements. Int J Radiat Oncol Biol Phys. 2005;61:583-593.
58. Munier FL, Verwey J, Pica A, et al. New developments in external beam radiotherapy for retinoblastoma: from lens to normal tissue-sparing techniques. Clin Experiment Ophthalmol. 2008;36:78-89.
59. Maelandsmo GM, Florenes VA, Hovig E, et al. Involvement of the pRb/p16/cdk4/cyclin D1 pathway in the tumorigenesis of sporadic malignant melanomas. Br J Cancer. 1996;73: 909-916.
60. Pappo AS. Rhabdomyosarcoma and other soft tissue sarcomas of childhood. Curr Opin Oncol. 1994;6:397-402.
61. Spunt SL, Rodriguez-Galindo C, Fuller CE, et al. Ewing sarcoma-family tumors that arise after treatment of primary childhood cancer. Cancer. 2006;107:201-206.
62. Sun A, Bagella L, Tutton S, et al. From G0 to S phase: a view of the roles played by the retinoblastoma (Rb) family members in the Rb-E2F pathway. J Cell Biochem. 2007;102: 1400-1404.
63. Sabado AC. Molecular biology of retinoblastoma. Clin Transl Oncol. 2008;10:389-394.
64. DeCaprio JA, Ludlow JW, Lynch D, et al. The product of the retinoblastoma susceptibility gene has properties of a cell cycle regulatory element. Cell. 1989;58:1085-1095.
65. Sherr CJ, McCormick F. The RB and p53 pathways in cancer. Cancer Cell. 2002;2:103-112.
66. Giacinti C, Giordano A. RB and cell cycle progression. Oncogene. 2006;25:5220-5227.
67. Van Deursen JM. Rb loss causes cancer by driving mitosis mad. Cancer Cell. 2007;11:1-3.
68. Genovese C, Trani D, Caputi M, et al. Cell cycle control and beyond: emerging roles for the retinoblastoma gene family. Oncogene. 2006;25:5201-5209.
69. Knudsen ES, Knudsen KE. Retinoblastoma tumor suppressor: where cancer meets the cell cycle. Exp Biol Med (Maywood). 2006;231:1271-1281.
70. Salim A, Wiknjosastro GH, Danukusumo D, et al. Fetal retinoblastoma. J Ultrasound Med. 1998;17:717-720.
71. Lohmann DR, Gallie BL. Retinoblastoma. Gene Rev. 2007.
72. Li FP, Fraumeni JF Jr. Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann Intern Med. 1969;71:747-752.
73. Tinat J, Bougeard G, Baert-Desurmont S, et al. 2009 Version of the chompret criteria for li fraumeni syndrome. J Clin Oncol. 2009;27:e108-e109; author reply e110.
74. Nichols KE, Malkin D, Garber JE, et al. Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers. Cancer Epidemiol Biomarkers Prev. 2001;10:83-87.
75. Lee SB, Kim SH, Bell DW, et al. Destabilization of CHK2 by a missense mutation associated with Li-Fraumeni Syndrome. Cancer Res. 2001;61:8062-8067.
76. Varley J. TP53, hChk2, and the Li-Fraumeni syndrome. Methods Mol Biol. 2003;222:117-129.
77. Birch JM, Heighway J, Teare MD, et al. Linkage studies in a Li-Fraumeni family with increased expression of p53 proteinbut no germline mutation in p53. Br J Cancer. 1994;70: 1176-1181.
78. Bougeard G, Baert-Desurmont S, Tournier I, et al. Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome. J Med Genet. 2006;43:531-533.
79. Gu J, Kawai H, Wiederschain D, et al. Mechanism of functional inactivation of a Li-Fraumeni syndrome p53 that has a mutation outside of the DNA-binding domain. Cancer Res. 2001;61:1741-1746.
80. Ruijs MW, Schmidt MK, Nevanlinna H, et al. The singlenucleotide polymorphism 309 in the MDM2 gene contributes to the Li-Fraumeni syndrome and related phenotypes. Eur J Hum Genet. 2007;15:110-114.
81. DeLeo AB, Jay G, Appella E, et al. Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse. Proc Natl Acad Sci U S A. 1979;76:2420-2424.
82. Chumakov PM, Iotsova VS, Georgiev GP. Isolation of a plasmid clone containing the mRNA sequence for mouse nonviral T-antigen. Dokl Akad Nauk SSSR. 1982;267: 1272-1275.
83. Matlashewski G, Lamb P, Pim D, et al. Isolation and characterization of a human p53 cDNA clone: expression of the human p53 gene. EMBO J. 1984;3:3257-3262.
84. Baker SJ, Fearon ER, Nigro JM, et al. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science. 1989;244:217-221.
85. Kern SE, Kinzler KW, Bruskin A, et al. Identification of p53 as a sequence-specific DNA-binding protein. Science. 1991;252:1708-1711.
86. Maltzman W, Czyzyk L. UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells. Mol Cell Biol. 1984;4:1689-1694.
87. Kuerbitz SJ, Plunkett BS, Walsh WV, et al. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci U S A. 1992;89:7491-7495.
88. Lowe SW, Schmitt EM, Smith SW, et al. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature. 1993;362:847-849.
89. Yonish-Rouach E, Resnitzky D, Lotem J, et al. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature. 1991;352:345-347.
90. Tomkova K, Tomka M, Zajac V. Contribution of p53, p63, and p73 to the developmental diseases and cancer. Neoplasma. 2008;55:177-181.
91. Matheu A, Maraver A, Serrano M. The Arf/p53 pathway in cancer and aging. Cancer Res. 2008;68:6031-6034.
92. Soussi T, Lozano G. p53 mutation heterogeneity in cancer. Biochem Biophys Res Commun. 2005;331:834-842.
93. Latonen L, Laiho M. Cellular UV damage responses- functions of tumor suppressor p53. Biochim Biophys Acta. 2005;1755:71-89.
94. Liu Y, Kulesz-Martin M. p53 protein at the hub of cellular DNA damage response pathways through sequence-specific and non-sequence-specific DNA binding. Carcinogenesis. 2001;22:851-860.
95. Ding HF, Fisher DE. Mechanisms of p53-mediated apoptosis. Crit Rev Oncog. 1998;9:83-98.
96. Zabkiewicz J, Clarke AR. DNA damage-induced apoptosis: insights from the mouse. Biochim Biophys Acta. 2004;1705: 17-25.
97. Okorokov AL. p53 in a crosstalk between DNA repair and cell cycle checkpoints. Cell Cycle. 2003;2:233-235.
98. Smith ML, Seo YR. p53 regulation of DNA excision repair pathways. Mutagenesis. 2002;17:149-156.
99. Taylor WR, Stark GR. Regulation of the G2/M transition by p53. Oncogene. 2001;20:1803-1815.
100. Murphy ME. Polymorphic variants in the p53 pathway. Cell Death Differ. 2006;13:916-920.
101. Petitjean A, Achatz MI, Borresen-Dale AL, et al. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene. 2007;26: 2157-2165.
102. Whibley C, Pharoah PD, Hollstein M. p53 polymorphisms: cancer implications. Nat Rev Cancer. 2009;9:95-107.
103. Zambetti GP. The p53 mutation "gradient effect" and its clinical implications. J Cell Physiol. 2007;213:370-373.
104. Varley JM, Evans DG, Birch JM. Li-Fraumeni syndrome-a molecular and clinical review. Br J Cancer. 1997;76:1-14.
105. Le Bihan C, Moutou C, Brugieres L, et al. ARCAD: a method for estimating age-dependent disease risk associated with mutation carrier status from family data. Genet Epidemiol. 1995;12:13-25.
106. Hisada M, Garber JE, Fung CY, et al. Multiple primary cancers in families with Li-Fraumeni syndrome. J Natl Cancer Inst. 1998;90:606-611.
107. Varley JM. Germline TP53 mutations and Li-Fraumeni syndrome. Hum Mutat. 2003;21:313-320.
108. Schneider KA, Li F. Li-Fraumeni Syndrome. Gene Rev. 2004.
109. Felix CA, Slavc I, Dunn M, et al. p53 gene mutations in pediatric brain tumors. Med Pediatr Oncol. 1995;25:431-436.
110. McIntyre JF, Smith-Sorensen B, Friend SH, et al. Germline mutations of the p53 tumor suppressor gene in children with osteosarcoma. J Clin Oncol. 1994;12:925-930.
111. Diller L, Sexsmith E, Gottlieb A, et al. Germline p53 mutations are frequently detected in young children with rhabdomyosarcoma. J Clin Invest. 1995;95:1606-1611.
112. Malkin D, Jolly KW, Barbier N, et al. Germline mutations of the p53 tumor-suppressor gene in children and young adults with second malignant neoplasms. N Engl J Med. 1992;326: 1309-1315.
113. Thull DL, Vogel VG. Recognition and management of hereditary breast cancer syndromes. Oncologist. 2004;9:13-24.
114. Wong P, Verselis SJ, Garber JE, et al. Prevalence of early onset colorectal cancer in 397 patients with classic Li- Fraumeni syndrome. Gastroenterology. 2006;130:73-79.
115. Steiner AL, Goodman AD, Powers SR. Study of a kindred with pheochromocytoma, medullary thyroid carcinoma, hyperparathyroidism and Cushing's disease: multiple endocrine neoplasia, type 2. Medicine (Baltimore). 1968;47: 371-409.
116. Lakhani VT, You YN, Wells SA. The multiple endocrine neoplasia syndromes. Annu Rev Med. 2007;58:253-265.
117. Piecha G, Chudek J, Wiecek A. Multiple endocrine neoplasia type 1. Eur J Intern Med. 2008;19:99-103.
118. Stratakis CA, Schussheim DH, Freedman SM, et al. Pituitary macroadenoma in a 5-year-old: an early expression of multiple endocrine neoplasia type 1. J Clin Endocrinol Metab. 2000;85:4776-4780.
119. Rix M, Hertel NT, Nielsen FC, et al. Cushing's disease in childhood as the first manifestation of multiple endocrine neoplasia syndrome type 1. Eur J Endocrinol. 2004;151:709-715.
120. De Krijger RR. Endocrine tumor syndromes in infancy and childhood. Endocr Pathol. 2004;15:223-226.
121. Mora J, Cascon A, Robledo M, et al. Pediatric paraganglioma: an early manifestation of an adult disease secondary to germline mutations. Pediatr Blood Cancer. 2006;47:785-789.
122. Doherty GM. Multiple endocrine neoplasia type 1. J Surg Oncol. 2005;89:143-150.
123. Agarwal SK, Kester MB, Debelenko LV, et al. Germline mutations of the MEN1 gene in familial multiple endocrine neoplasia type 1 and related states. Hum Mol Genet. 1997;6:1169-1175.
124. Tsukada T, Nagamura Y, Ohkura N. MEN1 gene and its mutations: basic and clinical implications. Cancer Sci. 2008.
125. Guru SC, Goldsmith PK, Burns AL, et al. Menin, the product of the MEN1 gene, is a nuclear protein. Proc Natl Acad Sci U S A. 1998;95:1630-1634.
126. Agarwal SK, Guru SC, Heppner C, et al. Menin interacts with the AP1 transcription factor JunD and represses JunDactivated transcription. Cell. 1999;96:143-152.
127. Marini F, Falchetti A, Del Monte F, et al. Multiple endocrine neoplasia type 2. Orphanet J Rare Dis. 2006;1:45.
128. Moore SW, Zaahl MG. Multiple endocrine neoplasia syndromes, children, Hirschsprung's disease and RET. Pediatr Surg Int. 2008;24:521-530.
129. Jimenez C, Hu MI, Gagel RF. Management of medullary thyroid carcinoma. Endocrinol Metab Clin North Am. 2008; 37:481-496.
130. Baloh RH, Enomoto H, Johnson EM Jr, et al. The GDNF family ligands and receptors-implications for neural development. Curr Opin Neurobiol. 2000;10:103-110.
131. Machens A, Brauckhoff M, Gimm O, et al. Risk-oriented approach to hereditary adrenal pheochromocytoma. Ann N Y Acad Sci. 2006;1073:417-428.
132. Klein I, Esik O, Homolya V, et al. Molecular genetic diagnostic program of multiple endocrine neoplasia type 2A and familial medullary thyroid carcinoma syndromes in Hungary. J Endocrinol. 2001;170:661-666.
133. Moore SW, Appfelstaedt J, Zaahl MG. Familial medullary carcinoma prevention, risk evaluation, and RET in children of families with MEN2. J Pediatr Surg. 2007;42:326-332.
134. Lodish MB, Stratakis CA. RET oncogene in MEN2, MEN2B, MTC and other forms of thyroid cancer. Expert Rev Anticancer Ther. 2008;8:625-632.
135. You YN, Lakhani VT, Wells SA Jr. The role of prophylactic surgery in cancer prevention. World J Surg. 2007;31:450-464.
136. Bonnin JM, Rubinstein LJ, Palmer NF, et al. The association of embryonal tumors originating in the kidney and in the brain. A report of seven cases. Cancer. 1984;54: 2137-2146.
137. Rorke LB, Packer R, Biegel J. Central nervous system atypical teratoid/rhabdoid tumors of infancy and childhood. J Neurooncol. 1995;24:21-28.
138. Besnard-Guerin C, Cavenee W, Newsham I. The t(11;22) (p15.5;q11.23) in a retroperitoneal rhabdoid tumor also includes a regional deletion distal to CRYBB2 on 22q. Genes Chromosomes Cancer. 1995;13:145-150.
139. Rosty C, Peter M, Zucman J, et al. Cytogenetic and molecular analysis of a t(1;22)(p36;q11.2) in a rhabdoid tumor with a putative homozygous deletion of chromosome 22. Genes Chromosomes Cancer. 1998;21:82-89.
140. Versteege I, Sevenet N, Lange J, et al. Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature. 1998;394:203-206.
141. Taylor MD, Gokgoz N, Andrulis IL, et al. Familial posterior fossa brain tumors of infancy secondary to germline mutation of the hSNF5 gene. Am J Hum Genet. 2000;66:1403-1406.
142. Sevenet N, Lellouch-Tubiana A, Schofield D, et al. Spectrum of hSNF5/INI1 somatic mutations in human cancer and genotype-phenotype correlations. Hum Mol Genet. 1999;8: 2359-2368.
143. Stojanova A, Penn LZ. The role of INI1/hSNF5 in gene regulation and cancer. Biochem Cell Biol. 2009;87:163-177.
144. Reisman D, Glaros S, Thompson EA. The SWI/SNF complex and cancer. Oncogene. 2009;28:1653-1668.
145. Halliday GM, Bock VL, Moloney FJ, et al. SWI/SNF: a chromatin-remodelling complex with a role in carcinogenesis. Int J Biochem Cell Biol. 2009;41:725-728.
146. Muchardt C, Yaniv M. When the SWI/SNF complex remodels the cell cycle. Oncogene. 2001;20:3067-3075.
147. Jeter JM, Kohlmann W, Gruber SB. Genetics of colorectal cancer. Oncology (Williston Park). 2006;20:269-276; discussion 285-286, 288-289.
148. Rowley PT. Inherited susceptibility to colorectal cancer. Annu Rev Med. 2005;56:539-554.
149. Lynch HT, Lynch JF, Lynch PM, et al. Hereditary colorectal cancer syndromes: molecular genetics, genetic counseling, diagnosis and management. Fam Cancer. 2008;7:27-39.
150. Gardner EJ. A genetic and clinical study of intestinal polyposis, a predisposing factor for carcinoma of the colon and rectum. Am J Hum Genet. 1951;3:167-176.
151. Gardner EJ, Woolf CM. Intestinal polyposis and carcinoma originating from a mutation in a family group. Cancer. 1952; 5:695-699.
152. Turcot J, Despres JP, St Pierre F. Malignant tumors of the central nervous system associated with familial polyposis of the colon: report of two cases. Dis Colon Rectum. 1959;2: 465-468.
153. Burt RW, Jasperson KW. APC-associated polyposis conditions. Gene Rev. 2008.
154. Kinzler KW, Nilbert MC, Su LK, et al. Identification of FAP locus genes from chromosome 5q21. Science. 1991;253: 661-665.
155. Groden J, Thliveris A, Samowitz W, et al. Identification and characterization of the familial adenomatous polyposis coli gene. Cell. 1991;66:589-600.
156. Ficari F, Cama A, Valanzano R, et al. APC gene mutations and colorectal adenomatosis in familial adenomatous polyposis. Br J Cancer. 2000;82:348-353.
157. Aoki K, Taketo MM. Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene. J Cell Sci. 2007; 120:3327-3335.
158. Dukes CE. The hereditary factor in polyposis intestini, or multiple adenomata. Cancer Rev. 1930;1930:241-256.
159. Dukes CE. Familial intestinal polyposis. J Clin Pathol. 1947;1:34-38.
160. Petersen GM, Slack J, Nakamura Y. Screening guidelines and premorbid diagnosis of familial adenomatous polyposis using linkage. Gastroenterology. 1991;100:1658-1664.
161. Waddell WR, Ganser GF, Cerise EJ, et al. Sulindac for polyposis of the colon. Am J Surg. 1989;157:175-179.
162. Al-Sukhni W, Aronson M, Gallinger S. Hereditary colorectal cancer syndromes: familial adenomatous polyposis and lynch syndrome. Surg Clin North Am. 2008;88:819-844.
163. Muto T, Bussey HJ, Morson BC. The evolution of cancer of the colon and rectum. Cancer. 1975;36:2251-2270.
164. Spirio L, Olschwang S, Groden J, et al. Alleles of the APC gene: an attenuated form of familial polyposis. Cell. 1993;75: 951-957.
165. Heimann TM, Bolnick K, Aufses AH Jr. Results of surgical treatment for familial polyposis coli. Am J Surg. 1986;152: 276-278.
166. Durno CA, Gallinger S. Genetic predisposition to colorectal cancer: new pieces in the pediatric puzzle. J Pediatr Gastroenterol Nutr. 2006;43:5-15.
167. Tulchinsky H, Keidar A, Strul H, et al. Extracolonic manifestations of familial adenomatous polyposis after proctocolectomy. Arch Surg. 2005;140:159-163; discussion 164.
168. Garber JE, Li FP, Kingston JE, et al. Hepatoblastoma and familial adenomatous polyposis. J Natl Cancer Inst. 1988; 80:1626-1628.
169. Giardiello FM, Offerhaus GJ, Krush AJ, et al. Risk of hepatoblastoma in familial adenomatous polyposis. J Pediatr. 1991;119:766-768.
170. Hirschman BA, Pollock BH, Tomlinson GE. The spectrum of APC mutations in children with hepatoblastoma from familial adenomatous polyposis kindreds. J Pediatr. 2005;147: 263-266.
171. Aretz S, Koch A, Uhlhaas S, et al. Should children at risk for familial adenomatous polyposis be screened for hepatoblastoma and children with apparently sporadic hepatoblastoma be screened for APC germline mutations? Pediatr Blood Cancer. 2006;47:811-818.
172. Haidle JL, Howe JR. Juvenile polyposis syndrome. Gene Rev. 2008.
173. Desai DC, Murday V, Phillips RK, et al. A survey of phenotypic features in juvenile polyposis. J Med Genet. 1998;35:476-481.
174. Chow E, Macrae F. A review of juvenile polyposis syndrome. J Gastroenterol Hepatol. 2005;20:1634-1640.
175. Heiss KF, Schaffner D, Ricketts RR, et al. Malignant risk in juvenile polyposis coli: increasing documentation in the pediatric age group. J Pediatr Surg. 1993;28:1188-1193.
176. Agnifili A, Verzaro R, Gola P, et al. Juvenile polyposis: case report and assessment of the neoplastic risk in 271 patients reported in the literature. Dig Surg. 1999;16:161-166.
177. Grotsky HW, Rickert RR, Smith WD, et al. Familial juvenile polyposis coli. A clinical and pathologic study of a large kindred. Gastroenterology. 1982;82:494-501.
178. Howe JR, Mitros FA, Summers RW. The risk of gastrointestinal carcinoma in familial juvenile polyposis. Ann Surg Oncol. 1998;5:751-756.
179. Calva D, Howe JR. Hamartomatous polyposis syndromes. Surg Clin North Am. 2008;88:779-817.
180. Howe JR, Roth S, Ringold JC, et al. Mutations in the SMAD4/DPC4 gene in juvenile polyposis. Science. 1998;280: 1086-1088.
181. Howe JR, Bair JL, Sayed MG, et al. Germline mutations of the gene encoding bone morphogenetic protein receptor 1A in juvenile polyposis. Nat Genet. 2001;28:184-187.
182. Nishanian TG, Waldman T. Interaction of the BMPR-IA tumor suppressor with a developmentally relevant splicing factor. Biochem Biophys Res Commun. 2004;323: 91-97.
183. Alberici P, Gaspar C, Franken P, et al. Smad4 haploinsufficiency: a matter of dosage. Pathogenetics. 2008;1:2.
184. Howe JR, Haidle JL, Lal G, et al. ENG mutations in MADH4/BMPR1A mutation negative patients with juvenile polyposis. Clin Genet. 2007;71:91-92.
185. Plon SE, Malkin D. Childhood cancer and heredity. In: Pizzo PA, Poplack DG, eds. Principles and Practice of Pediatric Oncology. Philadelphia, PA: Lippincott Williams & Wilkins; 2006:14-37.
186. Grosfeld JL, West KW. Generalized juvenile polyposis coli. Clinical management based on long-term observations. Arch Surg. 1986;121:530-534.
187. Lynch HT, Kimberling W, Albano WA, et al. Hereditary nonpolyposis colorectal cancer (Lynch syndromes I and II). I. Clinical description of resource. Cancer. 1985;56:934-938. (Pubitemid 15228294)
188. Lynch HT, Voorhees GJ, Lanspa SJ, et al. Pancreatic carcinoma and hereditary nonpolyposis colorectal cancer: a family study. Br J Cancer. 1985;52:271-273.
189. Tops CM, Wijnen JT, Griffioen G, et al. Presymptomatic diagnosis of familial adenomatous polyposis by bridging DNA markers. Lancet. 1989;2:1361-1363.
190. Lynch HT, De la Chapelle A. Genetic susceptibility to nonpolyposis colorectal cancer. J Med Genet. 1999;36:801-818.
191. Cunningham JM, Christensen ER, Tester DJ, et al. Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability. Cancer Res. 1998;58:3455-3460.
192. Veigl ML, Kasturi L, Olechnowicz J, et al. Biallelic inactivation of hMLH1 by epigenetic gene silencing, a novel mechanism causing human MSI cancers. Proc Natl Acad Sci U S A. 1998;95:8698-8702.
193. Spry M, Scott T, Pierce H, et al. DNA repair pathways and hereditary cancer susceptibility syndromes. Front Biosci. 2007;12:4191-4207.
194. Li GM. Mechanisms and functions of DNA mismatch repair. Cell Res. 2008;18:85-98.
195. Zhang Y, Yuan F, Presnell SR, et al. Reconstitution of 5'-directed human mismatch repair in a purified system. Cell. 2005;122:693-705.
196. Lynch HT, Lynch JF. Lynch syndrome: history and current status. Dis Markers. 2004;20:181-198.
197. Vasen HF. Clinical description of the Lynch syndrome (hereditary nonpolyposis colorectal cancer (HNPCC)). Fam Cancer. 2005;4:219-225.
198. Ferrari A, Rognone A, Casanova M, et al. Colorectal carcinoma in children and adolescents: the experience of the Istituto Nazionale Tumori of Milan, Italy. Pediatr Blood Cancer. 2008;50:588-593.
199. Galmiche L, Revillon Y, Sarnacki S, et al. (Lynch syndrome pediatric: about a case). Ann Pathol. 2004;24:621-623.
200. Hogarty MD, White PS, Sulman EP, et al. Mononucleotide repeat instability is infrequent in neuroblastoma. Cancer Genet Cytogenet. 1998;106:140-143.
201. Jackson CC, Holter S, Pollett A, et al. Cafe-au-lait macules and pediatric malignancy caused by biallelic mutations in the DNA mismatch repair (MMR) gene PMS2. Pediatr Blood Cancer. 2008;50:1268-1270.
202. Nakajima K, Fukuzawa M, Kusafuka T, et al. Brief report. Metachronous multiple colorectal cancer with genomic instability in a child. Med Pediatr Oncol. 1998;31:549-550.
203. Poley JW, Wagner A, Hoogmans MM, et al. Biallelic germline mutations of mismatch-repair genes: a possible cause for multiple pediatric malignancies. Cancer. 2007;109:2349-2356.
204. Uhrhammer N, Bignon YJ. Report of a family segregating mutations in both the APC and MSH2 genes: juvenile onset of colorectal cancer in a double heterozygote. Int J Colorectal Dis. 2008;23:1131-1135.
205. Korf BR. The phakomatoses. Clin Dermatol. 2005;23:78-84.
206. Holman JD, Dyer JA. Genodermatoses with malignant potential. Curr Opin Pediatr. 2007;19:446-454.
207. Von Recklinghausen FD. Über die multiplen fibrome der haut und ihre beziehung zu den multiplen neuromen in festschrift für rudolf virchow. Germany: Berlin; 1882.
208. Williams VC, Lucas J, Babcock MA, et al. Neurofibromatosis type 1 revisited. Pediatrics. 2009;123:124-133.
209. McClatchey AI. Neurofibromatosis. Annu Rev Pathol. 2007; 2:191-216.
210. Neurofibromatosis. Conference statement. National Institutes of Health Consensus Development Conference. Arch Neurol. 1988;45:575-578.
211. Gutmann DH, Aylsworth A, Carey JC, et al. The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA. 1997;278:51-57.
212. Ferner RE, Huson SM, Thomas N, et al. Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. J Med Genet. 2007;44:81-88.
213. Trovo-Marqui AB, Tajara EH. Neurofibromin: a general outlook. Clin Genet. 2006;70:1-13.
214. Basu TN, Gutmann DH, Fletcher JA, et al. Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients. Nature. 1992;356:713-715.
215. Harrisingh MC, Lloyd AC. Ras/Raf/ERK signalling and NF1. Cell Cycle. 2004;3:1255-1258.
216. De Schepper S, Boucneau J, Lambert J, et al. Pigment cellrelated manifestations in neurofibromatosis type 1: an overview. Pigment Cell Res. 2005;18:13-24.
217. Winship IM, Dudding TE. Lessons from the skin-cutaneous features of familial cancer. Lancet Oncol. 2008;9:462-472.
218. Ferner RE. Neurofibromatosis 1. Eur J Hum Genet. 2007;15: 131-138.
219. Friedrich RE, Kluwe L, Funsterer C, et al. Malignant peripheral nerve sheath tumors (MPNST) in neurofibromatosis type 1 (NF1): diagnostic findings on magnetic resonance images and mutation analysis of the NF1 gene. Anticancer Res. 2005;25:1699-1702.
220. Ferrari A, Bisogno G, Carli M. Management of childhood malignant peripheral nerve sheath tumor. Paediatr Drugs. 2007;9:239-248.
221. Pastar Z, Lipozencic J, Budimcic D, et al. Neurofibromatosis- review of the literature and case report. Acta Dermatovenerol Croat. 2006;14:167-171.
222. Binning MJ, Liu JK, Kestle JR, et al. Optic pathway gliomas: a review. Neurosurg Focus. 2007;23:E2.
223. Listernick R, Louis DN, Packer RJ, et al. Optic pathway gliomas in children with neurofibromatosis 1: consensus statement from the NF1 Optic Pathway Glioma Task Force. Ann Neurol. 1997;41:143-149.
224. Sylvester CL, Drohan LA, Sergott RC. Optic-nerve gliomas, chiasmal gliomas and neurofibromatosis type 1. Curr Opin Ophthalmol. 2006;17:7-11.
225. Hwang JM, Cheon JE, Wang KC. Visual prognosis of optic glioma. Childs Nerv Syst. 2008;24:693-698.
226. Listernick R, Ferner RE, Liu GT, et al. Optic pathway gliomas in neurofibromatosis-1: controversies and recommendations. Ann Neurol. 2007;61:189-198.
227. Lee AG. Neuroophthalmological management of optic pathway gliomas. Neurosurg Focus. 2007;23:E1.
228. Cappelli C, Grill J, Raquin M, et al. Long-term follow up of 69 patients treated for optic pathway tumours before the chemotherapy era. Arch Dis Child. 1998;79:334-338.
229. Matsui I, Tanimura M, Kobayashi N, et al. Neurofibromatosis type 1 and childhood cancer. Cancer. 1993;72:2746-2754.
230. Hartley AL, Birch JM, Marsden HB, et al. Neurofibromatosis in children with soft tissue sarcoma. Pediatr Hematol Oncol. 1988;5:7-16.
231. Woodruff JM, Chernik NL, Smith MC, et al. Peripheral nerve tumors with rhabdomyosarcomatous differentiation (malignant "Triton" tumors). Cancer. 1973;32:426-439.
232. Horiuchi T, Watanabe I, Hatta N, et al. NF1 gene mutation and acute myelogenous leukaemia. Eur J Cancer. 1994; 30A:129.
233. Ferrari A, Bisogno G, Macaluso A, et al. Soft-tissue sarcomas in children and adolescents with neurofibromatosis type 1. Cancer. 2007;109:1406-1412.
234. Lee MJ, Stephenson DA. Recent developments in neurofibromatosis type 1. Curr Opin Neurol. 2007;20:135-141.
235. Redmann C. Neurofibromatosis: a guide to care in the community. J Fam Health Care. 2007;17:95-97.
236. Radtke HB, Sebold CD, Allison C, et al. Neurofibromatosis type 1 in genetic counseling practice: recommendations of the National Society of Genetic Counselors. J Genet Couns. 2007;16:387-407.
237. Mautner VF, TatagibaM, Guthoff R, et al. Neurofibromatosis 2 in the pediatric age group. Neurosurgery. 1993;33:92-96.
238. Stettner GM, Rostasy KM, Ludwig HC, et al. Infratentorial meningioma in an 8-year-old child as first sign of neurofibromatosis type 2. Neuropediatrics. 2007;38:29-31.
239. Kinzler KW, Vogelstein B. Cancer. A gene for neurofibromatosis 2. Nature. 1993;363:495-496.
240. Okada T, You L, Giancotti FG. Shedding light on Merlin's wizardry. Trends Cell Biol. 2007;17:222-229.
241. Curto M, McClatchey AI. Nf2/Merlin: a coordinator of receptor signalling and intercellular contact. Br J Cancer. 2008;98:256-262.
242. Evans DG, Sainio M, Baser ME. Neurofibromatosis type 2. J Med Genet. 2000;37:897-904.
243. Crino PB, Nathanson KL, Henske EP. The tuberous sclerosis complex. N Engl J Med. 2006;355:1345-1356.
244. Schwartz RA, Fernandez G, Kotulska K, et al. Tuberous sclerosis complex: advances in diagnosis, genetics, and management. J Am Acad Dermatol. 2007;57:189-202.
245. Robertson FM, Cendron M, Klauber GT, et al. Renal cell carcinoma in association with tuberous sclerosis in children. J Pediatr Surg. 1996;31:729-730.
246. Allison JW, James CA, Figarola MS. Pediatric case of the day. Renal cell carcinoma in a child with tuberous sclerosis. Radiographics. 1999;19:1388-1389.
247. Lendvay TS, Broecker B, Smith EA. Renal cell carcinoma in a 2-year-old child with tuberous sclerosis. J Urol. 2002;168: 1131-1132.
248. Bosi G, Lintermans JP, Pellegrino PA, et al. The natural history of cardiac rhabdomyoma with and without tuberous sclerosis. Acta Paediatr. 1996;85:928-931.
249. Karnak I, Alehan D, Ekinci S, et al. Cardiac rhabdomyoma as an unusual mediastinal mass in a newborn. Pediatr Surg Int. 2007;23:811-814.
250. Nir A, Ekstein S, Nadjari M, et al. Rhabdomyoma in the fetus: illustration of tumor growth during the second half of gestation. Pediatr Cardiol. 2001;22:515-518.
251. Cuccia V, Zuccaro G, Sosa F, et al. Subependymal giant cell astrocytoma in children with tuberous sclerosis. Childs Nerv Syst. 2003;19:232-243.
252. De Ribaupierre S, Dorfmuller G, Bulteau C, et al. Subependymal giant-cell astrocytomas in pediatric tuberous sclerosis disease: when should we operate? Neurosurgery. 2007;60:83-89; discussion 89-90.
253. Sinson G, Sutton LN, Yachnis AT, et al. Subependymal giant cell astrocytomas in children. Pediatr Neurosurg. 1994;20: 233-239.
254. Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell. 1993;75:1305-1315.
255. Humphrey D, Kwiatkowska J, Henske EP, et al. Cloning and evaluation of RALGDS as a candidate for the tuberous sclerosis gene TSC1. Ann Hum Genet. 1997;61:299-305. (Pubitemid 27455300)
256. Huang J, Manning BD. The TSC1-TSC2 complex: a molecular switchboard controlling cell growth. Biochem J. 2008;412:179-190.
257. Inoki K, Guan KL. Tuberous sclerosis complex, implication from a rare genetic disease to common cancer treatment. Hum Mol Genet. 2009;18:R94-R100.
258. Curatolo P, Bombardieri R, Jozwiak S. Tuberous sclerosis. Lancet. 2008;372:657-668.
259. Roach ES, Sparagana SP. Diagnosis of tuberous sclerosis complex. J Child Neurol. 2004;19:643-649.
260. Baskin HJ Jr. The pathogenesis and imaging of the tuberous sclerosis complex. Pediatr Radiol. 2008;38:936-952.
261. Shehata BM, Stockwell CA, Castellano-Sanchez AA, et al. Von Hippel-Lindau (VHL) disease: an update on the clinicopathologic and genetic aspects. Adv Anat Pathol. 2008;15: 165-171.
262. Von Hippel E. Ueber eine sehr seltene Erkrankung der Netzhaut. Albrecht von Graefes Arch Ophthal. 1904;59: 83-106.
263. Lindau A. Zur Frage der Angiomatosis Retinae und Ihrer Hirncomplikation. Acta Ophthal. 1927;4:193-226.
264. Parast MM, Eudy G, Gow KW, et al. A unique case of renal carcinoma with Xp11.2 translocations/TFE3 gene fusions in a 3-year-old child, with coexistent von Hippel-Lindau gene mutation. Pediatr Dev Pathol. 2004;7:403-406.
265. Latif F, Tory K, Gnarra J, et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science. 1993;260:1317-1320. (Pubitemid 23231974)
266. Kim WY, Kaelin WG. Role of VHL gene mutation in human cancer. J Clin Oncol. 2004;22:4991-5004.
267. Kaelin WG. Von Hippel-Lindau disease. Annu Rev Pathol. 2007;2:145-173.
268. Frew IJ, Krek W. Multitasking by pVHL in tumour suppression. Curr Opin Cell Biol. 2007;19:685-690.
269. Simpson JL, Carson SA, Cisneros P. Preimplantation genetic diagnosis (PGD) for heritable neoplasia. J Natl Cancer Inst Monogr. 2005;34:87-90.
270. Gorlin RJ, Goltz RW.Multiple nevoid basal-cell epithelioma, jaw cysts and bifid rib. A syndrome. N Engl J Med. 1960;262:908-912.
271. Cowan R, Hoban P, Kelsey A, et al. The gene for the naevoid basal cell carcinoma syndrome acts as a tumoursuppressor gene in medulloblastoma. Br J Cancer. 1997;76: 141-145.
272. Kimonis VE, Mehta SG, Digiovanna JJ, et al. Radiological features in 82 patients with nevoid basal cell carcinoma (NBCC or Gorlin) syndrome. Genet Med. 2004;6:495-502.
273. Gorlin RJ. Nevoid basal-cell carcinoma syndrome. Medicine (Baltimore). 1987;66:98-113.
274. Herzberg JJ, Wiskemann A. (The fifth phakomatosis. Basal cell nevus with hereditary malformation and medulloblastoma). Dermatologica. 1963;126:106-123.
275. Kimonis VE, Goldstein AM, Pastakia B, et al. Clinical manifestations in 105 persons with nevoid basal cell carcinoma syndrome. Am J Med Genet. 1997;69:299-308.
276. Amlashi SF, Riffaud L, Brassier G, et al. Nevoid basal cell carcinoma syndrome: relation with desmoplastic medulloblastoma in infancy. A population-based study and review of the literature. Cancer. 2003;98:618-624.
277. Walter AW, Pivnick EK, Bale AE, et al. Complications of the nevoid basal cell carcinoma syndrome: a case report. J Pediatr Hematol Oncol. 1997;19:258-262.
278. Romke C, Godde-Salz E, Grote W. Investigations of chromosomal stability in the Gorlin-Goltz syndrome. Arch Dermatol Res. 1985;277:370-372.
279. Garre ML, Cama A, Bagnasco F, et al. Medulloblastoma variants: age-dependent occurrence and relation to Gorlin syndrome-a new clinical perspective. Clin Cancer Res. 2009;15:2463-2471.
280. Pastorino L, Cusano R, Nasti S, et al. Molecular characterization of Italian nevoid basal cell carcinoma syndrome patients. Hum Mutat. 2005;25:322-323.
281. Lo Muzio L. Nevoid basal cell carcinoma syndrome (Gorlin syndrome). Orphanet J Rare Dis. 2008;3:32.
282. Rubinstein WS. Hereditary breast cancer: pathobiology, clinical translation, and potential for targeted cancer therapeutics. Fam Cancer. 2008;7:83-89.
283. Lynch HT, Silva E, Snyder C, et al. Hereditary breast cancer: part I. Diagnosing hereditary breast cancer syndromes. Breast J. 2008;14:3-13.
284. Wang W. Emergence of a DNA-damage response network consisting of Fanconi anaemia and BRCA proteins. Nat Rev Genet. 2007;8:735-748.
285. Alpi AF, Patel KJ. Monoubiquitylation in the Fanconi anemia DNA damage response pathway. DNA Repair (Amst). 2009;8:430-435.
286. Yoshida K, Miki Y. Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage. Cancer Sci. 2004;95:866-871.
287. Schubert EL, Lee MK, Mefford HC, et al. BRCA2 in American families with four or more cases of breast or ovarian cancer: recurrent and novel mutations, variable expression, penetrance, and the possibility of families whose cancer is not attributable to BRCA1 or BRCA2. Am J Hum Genet. 1997;60:1031-1040.
288. Andressoo JO, Hoeijmakers JH, Mitchell JR. Nucleotide excision repair disorders and the balance between cancer and aging. Cell Cycle. 2006;5:2886-2888.
289. Dworaczek H, Xiao W. Xeroderma pigmentosum: a glimpse into nucleotide excision repair, genetic instability, and cancer. Crit Rev Oncog. 2007;13:159-177.
290. Nouspikel T. DNA repair in mammalian cells: Nucleotide excision repair: variations on versatility. Cell Mol Life Sci. 2009;66:994-1009.
291. Shuck SC, Short EA, Turchi JJ. Eukaryotic nucleotide excision repair: from understanding mechanisms to influencing biology. Cell Res. 2008;18:64-72.
292. Webb S. Xeroderma pigmentosum. BMJ. 2008;336:444-446.
293. Nouspikel T. Nucleotide excision repair and neurological diseases. DNA Repair (Amst). 2008;7:1155-1167.
294. Bergoglio V, Magnaldo T. Nucleotide excision repair and related human diseases. Genome Dyn. 2006;1:35-52.
295. Leibeling D, Laspe P, Emmert S. Nucleotide excision repair and cancer. J Mol Histol. 2006;37:225-238.
296. Daya-Grosjean L. Xeroderma pigmentosum and skin cancer. Adv Exp Med Biol. 2008;637:19-27.
297. Norgauer J, Idzko M, Panther E, et al. Xeroderma pigmentosum. Eur J Dermatol. 2003;13:4-9.
298. Alcalay J, Ben-Amitai D, Alkalay R. Idiopathic basal cell carcinoma in children. J Drugs Dermatol. 2008;7:479-481.
299. Pappo AS. Melanoma in children and adolescents. Eur J Cancer. 2003;39:2651-2661.
300. Cleaver JE. Cancer in xeroderma pigmentosum and related disorders of DNA repair. Nat Rev Cancer. 2005;5:564-573.
301. Moriwaki S, Kraemer KH. Xeroderma pigmentosum- bridging a gap between clinic and laboratory. Photodermatol Photoimmunol Photomed. 2001;17:47-54.
302. Rapin I, Lindenbaum Y, Dickson DW, et al. Cockayne syndrome and xeroderma pigmentosum. Neurology. 2000;55: 1442-1449.
303. Arenas-Sordo ML, Hernandez-Zamora E, Montoya-Perez LA, et al. Cockayne's syndrome: a case report. Literature review. Med Oral Patol Oral Cir Bucal. 2006;11:E236-E238.
304. Charles CA, Connelly EA, Aber CG, et al. A rare presentation of squamous cell carcinoma in a patient with PIBIDS-type trichothiodystrophy. Pediatr Dermatol. 2008;25: 264-267.
305. Hickson ID. RecQ helicases: caretakers of the genome. Nat Rev Cancer. 2003;3:169-178.
306. Harrigan JA, Bohr VA. Human diseases deficient in RecQ helicases. Biochimie. 2003;85:1185-1193.
307. Hanada K, Hickson ID. Molecular genetics of RecQ helicase disorders. Cell Mol Life Sci. 2007;64:2306-2322.
308. Bohr VA. Rising from the RecQ-age: the role of human RecQ helicases in genome maintenance. Trends Biochem Sci. 2008;33:609-620.
309. Seki M, Otsuki M, Ishii Y, et al. RecQ family helicases in genome stability: lessons from gene disruption studies in DT40 cells. Cell Cycle. 2008;7:2472-2478.
310. Ozgenc A, Loeb LA. Werner Syndrome, aging and cancer. Genome Dyn. 2006;1:206-217.
311. Amor-Gueret M. Bloom syndrome, genomic instability and cancer: the SOS-like hypothesis. Cancer Lett. 2006;236:1-12.
312. Kaneko H, Kondo N. Clinical features of bloom syndrome and function of the causative gene, BLM helicase. Expert Rev Mol Diagn. 2004;4:393-401.
313. German J. Bloom's syndrome. Dermatol Clin. 1995;13:7-18.
314. Larizza L, Magnani I, Roversi G. Rothmund-Thomson syndrome and RECQL4 defect: splitting and lumping. Cancer Lett. 2006;232:107-120.
315. Wang LL, Levy ML, Lewis RA, et al. Clinical manifestations in a cohort of 41 Rothmund-Thomson syndrome patients. Am J Med Genet. 2001;102:11-17.
316. Vennos EM, James WD. Rothmund-Thomson syndrome. Dermatol Clin. 1995;13:143-150.
317. Frappart PO, McKinnon PJ. Ataxia-telangiectasia and related diseases. Neuromolecular Med. 2006;8:495-511.
318. Berkel AI, Ersoy F. Ataxia-telangiectasia and malignancies. Turk J Pediatr. 1974;26:82-89.
319. Cunlift PN, Mann JR, Cameron AH, et al. Radiosensitivity in ataxia-telangiectasia. Br J Radiol. 1975;48:374-376.
320. Lavin MF. Ataxia-telangiectasia: from a rare disorder to a paradigm for cell signalling and cancer. Nat Rev Mol Cell Biol. 2008;9:759-769.
321. Hosking G. Ataxia telangiectasia. Dev Med Child Neurol. 1982;24:77-80.
322. Perlman S, Becker-Catania S, Gatti RA. Ataxia-telangiectasia: diagnosis and treatment. Semin Pediatr Neurol. 2003;10:173-182.
323. Peterson RD, Kelly WD, Good RA. Ataxia-telangiectasia. its association with a defective thymus, immunologicaldeficiency disease, and malignancy. Lancet. 1964;1:1189-1193.
324. Nowak-Wegrzyn A, Crawford TO, Winkelstein JA, et al. Immunodeficiency and infections in ataxia-telangiectasia. J Pediatr. 2004;144:505-511.
325. Taylor AM, Byrd PJ. Molecular pathology of ataxia telangiectasia. J Clin Pathol. 2005;58:1009-1015.
326. Eyfjord JE, Bodvarsdottir SK. Genomic instability and cancer: networks involved in response to DNA damage. Mutat Res. 2005;592:18-28.
327. Lavin MF, Kozlov S. ATM activation and DNA damage response. Cell Cycle. 2007;6:931-942.
328. Banin S, Moyal L, Shieh S, et al. Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science. 1998;281:1674-1677.
329. Lim DS, Kim ST, Xu B, et al. ATM phosphorylates p95/nbs1 in an S-phase checkpoint pathway. Nature. 2000;404:613-617.
330. Canman CE, Lim DS, Cimprich KA, et al. Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science. 1998;281:1677-1679.
331. Wong KK, Maser RS, Bachoo RM, et al. Telomere dysfunction and Atm deficiency compromises organ homeostasis and accelerates ageing. Nature. 2003;421:643-648.
332. Tibbetts RS, Brumbaugh KM, Williams JM, et al. A role for ATR in the DNA damage-induced phosphorylation of p53. Genes Dev. 1999;13:152-157.
333. Park BJ, Kang JW, Lee SW, et al. The haploinsufficient tumor suppressor p18 upregulates p53 via interactions with ATM/ATR. Cell. 2005;120:209-221.
334. Cavaciuti E, Lauge A, Janin N, et al. Cancer risk according to type and location of ATM mutation in ataxia-telangiectasia families. Genes Chromosomes Cancer. 2005;42:1-9.
335. Lu S, Shen K, Wang Y, et al. Atm-haploinsufficiency enhances susceptibility to carcinogen-induced mammary tumors. Carcinogenesis. 2006;27:848-855.
336. Ahmed M, Rahman N. ATM and breast cancer susceptibility. Oncogene. 2006;25:5906-5911.
337. Swift M, Sholman L, Perry M, et al. Malignant neoplasms in the families of patients with ataxia-telangiectasia. Cancer Res. 1976;36:209-215.
338. Khanna KK. Cancer risk and the ATM gene: a continuing debate. J Natl Cancer Inst. 2000;92:795-802.
339. Angele S, Romestaing P, Moullan N, et al. ATM haplotypes and cellular response to DNA damage: association with breast cancer risk and clinical radiosensitivity. Cancer Res. 2003;63:8717-8725.
340. Olsen JH, Hahnemann JM, Borresen-Dale AL, et al. Breast and other cancers in 1445 blood relatives of 75 Nordic patients with ataxia telangiectasia. Br J Cancer. 2005;93: 260-265.
341. Soukupova J, Dundr P, Kleibl Z, et al. Contribution of mutations in ATM to breast cancer development in the Czech population. Oncol Rep. 2008;19:1505-1510.
342. Fanconi G. Familiäre, infantile perniciosähnliche Anämie (perniziöses Blutbild und Konstitution). Jahrbuch für Kinderheilkunde und physische Erziehung, Wien. 1927;117: 257-280.
343. Lobitz S, Velleuer E. Guido Fanconi (1892-1979): a jack of all trades. Nat Rev Cancer. 2006;6:893-898.
344. Green AM, Kupfer GM. Fanconi anemia. Hematol Oncol Clin North Am. 2009;23:193-214.
345. D'Andrea AD, Dahl N, Guinan EC, et al. Marrow failure. Hematol Am Soc Hematol Educ Program. 2002:58-72.
346. Dokal I. Fanconi's anaemia and related bone marrow failure syndromes. Br Med Bull. 2006;77-78:37-53.
347. Alter BP. Fanconi's anemia, transplantation, and cancer. Pediatr Transplant. 2005;9(suppl 7):81-86.
348. Auerbach AD, Weiner MA, Warburton D, et al. Acute myeloid leukemia as the first hematologic manifestation of Fanconi anemia. Am J Hematol. 1982;12:289-300.
349. Vaitiekaitis AS, Grau WH. Squamous cell carcinoma of the mandible in Franconi anemia: report of case. J Oral Surg. 1980;38:372-373.
350. Kew MC, Van Coller B, Prowse CM, et al. Occurrence of primary hepatocellular cancer and peliosis hepatis after treatment with androgenic steroids. S Afr Med J. 1976;50: 1233-1237.
351. Sarna G, Tomasulo P, Lotz MJ, et al. Multiple neoplasms in two siblings with a variant form of Fanconi's anemia. Cancer. 1975;36:1029-1033.
352. Holder LE, Gnarra DJ, Lampkin BC, et al. Hepatoma associated with anabolic steroid therapy. Am J Roentgenol Radium Ther Nucl Med. 1975;124:638-642.
353. D'Andrea AD. The Fanconi road to cancer. Genes Dev. 2003;17:1933-1936.
354. Reinhard H, Peters I, Gottschling S, et al. Squamous cell carcinoma of the tongue in a 13-year-old girl with Fanconi anemia. J Pediatr Hematol Oncol. 2007;29:488-491.
355. De Winter JP, Joenje H. The genetic and molecular basis of Fanconi anemia. Mutat Res. 2008;668:11-19.
356. Taniguchi T, D'Andrea AD. Molecular pathogenesis of Fanconi anemia: recent progress. Blood. 2006;107: 4223-4233.
357. Jacquemont C, Taniguchi T. The Fanconi anemia pathway and ubiquitin. BMC Biochem. 2007;8(suppl 1):S10.
358. Smogorzewska A, Matsuoka S, Vinciguerra P, et al. Identification of the FANCI protein, a monoubiquitinated FANCD2 paralog required for DNA repair. Cell. 2007;129: 289-301.
359. Taniguchi T, Garcia-Higuera I, Xu B, et al. Convergence of the fanconi anemia and ataxia telangiectasia signaling pathways. Cell. 2002;109:459-472.
360. Patel KJ, Joenje H. Fanconi anemia and DNA replication repair. DNA Repair (Amst). 2007;6:885-890.
361. Nakanishi K, Yang YG, Pierce AJ, et al. Human Fanconi anemia monoubiquitination pathway promotes homologous DNA repair. Proc Natl Acad Sci U S A. 2005;102:1110-1115.
362. Andreassen PR, Ren K. Fanconi anemia proteins, DNA interstrand crosslink repair pathways, and cancer therapy. Curr Cancer Drug Targets. 2009;9:101-117.
363. Mathew CG. Fanconi anaemia genes and susceptibility to cancer. Oncogene. 2006;25:5875-5884.
364. Rosenberg PS, Alter BP, Ebell W. Cancer risks in Fanconi anemia: findings from the German Fanconi Anemia Registry. Haematologica. 2008;93:511-517.
365. Howlett NG, Taniguchi T, Olson S, et al. Biallelic inactivation of BRCA2 in Fanconi anemia. Science. 2002;297: 606-609.
366. Saadatzadeh MR, Bijangi-Vishehsaraei K, Kapur R, et al. Distinct roles of stress-activated protein kinases in Fanconi anemia-type C-deficient hematopoiesis. Blood. 2009;113: 2655-2660.
367. Thompson LH, Hinz JM, Yamada NA, et al. How Fanconi anemia proteins promote the four Rs: replication, recombination, repair, and recovery. Environ Mol Mutagen. 2005;45: 128-142.
368. Levitus M, Joenje H, De Winter JP. The Fanconi anemia pathway of genomic maintenance. Cell Oncol. 2006;28:3-29. (Pubitemid 43673124)
369. Mehta PA, Ileri T, Harris RE, et al. Chemotherapy for myeloid malignancy in children with Fanconi anemia. Pediatr Blood Cancer. 2007;48:668-672.
370. Goldsby RE, Perkins SL, Virshup DM, et al. Lymphoblastic lymphoma and excessive toxicity from chemotherapy: an unusual presentation for Fanconi anemia. J Pediatr Hematol Oncol. 1999;21:240-243.
371. Flowers ME, Zanis J, Pasquini R, et al. Marrow transplantation for Fanconi anaemia: conditioning with reduced doses of cyclophosphamide without radiation. Br J Haematol. 1996; 92:699-706.
372. Gluckman E. Radiosensitivity in Fanconi anemia: application to the conditioning for bone marrow transplantation. Radiother Oncol. 1990;18(suppl 1):88-93.
373. Alter BP. Radiosensitivity in Fanconi's anemia patients. Radiother Oncol. 2002;62:345-347.
374. Tsirigotis P, Sella T, Shapira MY, et al. Peliosis hepatis following treatment with androgen-steroids in patients with bone marrow failure syndromes. Haematologica. 2007;92: e106-e110.
375. Resnick MB, Kozakewich HP, Perez-Atayde AR. Hepatic adenoma in the pediatric age group. Clinicopathological observations and assessment of cell proliferative activity. Am J Surg Pathol. 1995;19:1181-1190.
376. Touraine RL, Bertrand Y, Foray P, et al. Hepatic tumours during androgen therapy in Fanconi anaemia. Eur J Pediatr. 1993;152:691-693.
377. Tischkowitz M, Dokal I. Fanconi anaemia and leukaemiaclinical and molecular aspects. Br J Haematol. 2004;126: 176-191.
378. Myers KC, Davies SM. Hematopoietic stem cell transplantation for bone marrow failure syndromes in children. Biol Blood Marrow Transplant. 2009;15:279-292.
379. Kook H. Fanconi anemia: current management. Hematology. 2005;10(suppl 1):108-110.
380. Alter BP, Lipton JM. Fanconi Anemia. eMedicine. 2007.
381. Garcia MJ, Benitez J. The Fanconi anaemia/BRCA pathway and cancer susceptibility. Searching for new therapeutic targets. Clin Transl Oncol. 2008;10:78-84.
382. Dufour C, Svahn J. Fanconi anaemia: new strategies. Bone Marrow Transplant. 2008;41(suppl 2):S90-5.
383. Varan A. Wilms' tumor in children: an overview. Nephron Clin Pract. 2008;108:c83-c90.
384. Miller RW, Fraumeni JF Jr, Manning MD. Association of wilms's tumor with aniridia, hemihypertrophy and other congenital malformations. N Engl J Med. 1964;270:922-927.
385. Xu S, Han JC, Morales A, et al. Characterization of 11p14- p12 deletion in WAGR syndrome by array CGH for identifying genes contributing to mental retardation and autism. Cytogenet Genome Res. 2008;122:181-187.
386. Breslow NE, Takashima JR, Ritchey ML, et al. Renal failure in the Denys-Drash and Wilms' tumor-aniridia syndromes. Cancer Res. 2000;60:4030-4032.
387. Dahan K, Kamal M, Noel LH, et al. Small glomeruli in WAGR (Wilms Tumor, Aniridia, Genitourinary Anomalies and Mental Retardation) syndrome. Am J Kidney Dis. 2007;49:793-800.
388. Breslow NE, Norris R, Norkool PA, et al. Characteristics and outcomes of children with the Wilms tumor-Aniridia syndrome: a report from the National Wilms Tumor Study Group. J Clin Oncol. 2003;21:4579-4585.
389. Denys P, Malvaux P, Van Den Berghe H, et al. Association of an anatomo-pathological syndrome of male pseudohermaphroditism, Wilms' tumor, parenchymatous nephropathy and XX/XY mosaicism. Arch Fr Pediatr. 1967;24: 729-739.
390. Drash A, Sherman F, Hartmann WH, et al. A syndrome of pseudohermaphroditism, Wilms' tumor, hypertension, and degenerative renal disease. J Pediatr. 1970;76: 585-593.
391. Moorthy AV, Chesney RW, Lubinsky M. Chronic renal failure and XY gonadal dysgenesis: "Frasier" syndrome-a commentary on reported cases. Am J Med Genet Suppl. 1987;3:297-302.
392. Frasier SD, Bashore RA, Mosier HD. Gonadoblastoma associated with pure gonadal dysgenesis in monozygous twins. J Pediatr. 1964;64:740-745.
393. Auber F, Jeanpierre C, Denamur E, et al. Management of Wilms tumors in Drash and Frasier syndromes. Pediatr Blood Cancer. 2009;52:55-59.
394. Barbaux S, Niaudet P, Gubler MC, et al. Donor splice-site mutations in WT1 are responsible for Frasier syndrome. Nat Genet. 1997;17:467-470.
395. Klamt B, Koziell A, Poulat F, et al. Frasier syndrome is caused by defective alternative splicing of WT1 leading to an altered ratio of WT1 +/-KTS splice isoforms. Hum Mol Genet. 1998;7:709-714.
396. Wiedemann HR. Familial Malformation Complex with Umbilical Hernia and Macroglossia-a "New Syndrome"? J Genet Hum. 1964;13:223-232.
397. Beckwith J. Macroglossia, omphalocele, adrenal cytomegaly, gigantism, and hyperplastic visceromegaly. Birth Defects. 1969;5:188.
398. Weksberg R, Shuman C, Smith AC. Beckwith-Wiedemann syndrome. Am J Med Genet C Semin Med Genet. 2005; 137C:12-23.
399. Engstrom W, Lindham S, Schofield P. Wiedemann-Beckwith syndrome. Eur J Pediatr. 1988;147:450-457.
400. DeBaun MR, Niemitz EL, Feinberg AP. Association of in vitro fertilization with Beckwith-Wiedemann syndrome and epigenetic alterations of LIT1 and H19. Am J Hum Genet. 2003;72:156-160.
401. Rump P, Zeegers MP, Van Essen AJ. Tumor risk in Beckwith-Wiedemann syndrome: a review and meta-analysis. Am J Med Genet A. 2005;136:95-104.
402. Henry I, Bonaiti-Pellie C, Chehensse V, et al. Uniparental paternal disomy in a genetic cancer-predisposing syndrome. Nature. 1991;351:665-667.
403. Tay JS. Molecular genetics of Wilms' tumour. J Paediatr Child Health. 1995;31:379-383.
404. Reik W, Brown KW, Slatter RE, et al. Allelic methylation of H19 and IGF2 in the Beckwith-Wiedemann syndrome. Hum Mol Genet. 1994;3:1297-1301.
405. Schneid H, Seurin D, Vazquez MP, et al. Parental allele specific methylation of the human insulin-like growth factor II gene and Beckwith-Wiedemann syndrome. J Med Genet. 1993;30:353-362.
406. Lee MP, DeBaun M, Randhawa G, et al. Low frequency of p57KIP2 mutation in Beckwith-Wiedemann syndrome. Am J Hum Genet. 1997;61:304-309.
407. Journel H, Lucas J, Allaire C, et al. Trisomy 11p15 and Beckwith-Wiedemann syndrome. Report of two new cases. Ann Genet. 1985;28:97-101.
408. Turleau C, de Grouchy J, Chavin-Colin F, et al. Trisomy 11p15 and Beckwith-Wiedemann syndrome. A report of two cases. Hum Genet. 1984;67:219-221.
409. Schneid H, Vazquez MP, Vacher C, et al. The Beckwith- Wiedemann syndrome phenotype and the risk of cancer. Med Pediatr Oncol. 1997;28:411-415.
410. DeBaun MR, Tucker MA. Risk of cancer during the first four years of life in children from The Beckwith-Wiedemann Syndrome Registry. J Pediatr. 1998;132:398-400.
411. Choyke PL, Siegel MJ, Craft AW, et al. Screening for Wilms tumor in children with Beckwith-Wiedemann syndrome or idiopathic hemihypertrophy. Med Pediatr Oncol. 1999;32: 196-200.
412. Ward A. Beck-Wiedemann syndrome and Wilms' tumour. Mol Hum Reprod. 1997;3:157-168.
413. Clericuzio CL. Clinical phenotypes and Wilms tumor. Med Pediatr Oncol. 1993;21:182-187.
414. Cohen MM Jr. Overgrowth syndromes: an update. Adv Pediatr. 1999;46:441-491.
415. Lapunzina P. Risk of tumorigenesis in overgrowth syndromes: a comprehensive review. Am J Med Genet C Semin Med Genet. 2005;137C:53-71. (Pubitemid 41113663)
416. Neri G, Marini R, Cappa M, et al. Simpson-Golabi-Behmel syndrome: an X-linked encephalo-tropho-schisis syndrome. Am J Med Genet. 1988;30:287-299.
417. Pilia G, Hughes-Benzie RM, MacKenzie A, et al. Mutations in GPC3, a glypican gene, cause the Simpson-Golabi-Behmel overgrowth syndrome. Nat Genet. 1996;12:241-247.
418. Shi W, Filmus J. A patient with the Simpson-Golabi-Behmel syndrome displays a loss-of-function point mutation in GPC3 that inhibits the attachment of this proteoglycan to the cell surface. Am J Med Genet A. 2009;149A:552-554.
419. Mariani S, Iughetti L, Bertorelli R, et al. Genotype/phenotype correlations of males affected by Simpson-Golabi- Behmel syndrome with GPC3 gene mutations: patient report and review of the literature. J Pediatr Endocrinol Metab. 2003;16:225-232.
420. DeBaun MR, Ess J, Saunders S. Simpson Golabi Behmel syndrome: progress toward understanding the molecular basis for overgrowth, malformation, and cancer predisposition. Mol Genet Metab. 2001;72:279-286.
421. Hughes-Benzie RM, Pilia G, Xuan JY, et al. Simpson-Golabi- Behmel syndrome: genotype/phenotype analysis of 18 affected males from 7 unrelated families. Am J Med Genet. 1996;66: 227-234.
422. Tattelbaum AG, Dufresne CR. Proteus syndrome: a newly recognized hamartomatous syndrome with significant craniofacial dysmorphology. J Craniofac Surg. 1995;6:151-160.
423. Biesecker LG, Happle R, Mulliken JB, et al. Proteus syndrome: diagnostic criteria, differential diagnosis, and patient evaluation. Am J Med Genet. 1999;84:389-395.
424. Biesecker L. The challenges of Proteus syndrome: diagnosis and management. Eur J Hum Genet. 2006;14:1151-1157.
425. Dragieva G, Stahel HU, Meyer M, et al. Proteus syndrome. Vasa. 2003;32:159-163.
426. Eng C, Thiele H, Zhou XP, et al. PTEN mutations and proteus syndrome. Lancet. 2001;358:2079-2080.
427. Biesecker LG, Rosenberg MJ, Vacha S, et al. PTEN mutations and proteus syndrome. Lancet. 2001;358:2079-2080.
428. Rosner M, Hanneder M, Siegel N, et al. The mTOR pathway and its role in human genetic diseases. Mutat Res. 2008; 659:284-292.
429. Tatton-Brown K, Rahman N. Sotos syndrome. Eur J Hum Genet. 2007;15:264-271.
430. Baujat G, Cormier-Daire V. Sotos syndrome. Orphanet J Rare Dis. 2007;2:36.
431. Kurotaki N, Imaizumi K, Harada N, et al. Haploinsufficiency of NSD1 causes Sotos syndrome. Nat Genet. 2002;30: 365-366.
432. Martinez-Glez V, Lapunzina P. Sotos syndrome is associated with leukemia/lymphoma. Am J Med Genet A. 2007;143A: 1244-1245.
433. Jin Y, Chen RL, Wang PJ, et al. Sacrococcygeal germ cell tumor and spinal deformity in association with Sotos syndrome. Med Pediatr Oncol. 2002;38:133-134.
434. Leonard NJ, Cole T, Bhargava R, et al. Sacrococcygeal teratoma in two cases of Sotos syndrome. Am J Med Genet. 2000;95:182-184.
435. Le Marec B, Pasquier L, Dugast C, et al. Gastric carcinoma in Sotos syndrome (cerebral gigantism). Ann Genet. 1999;42: 113-116.
436. Nance MA, Neglia JP, Talwar D, et al. Neuroblastoma in a patient with Sotos' syndrome. J Med Genet. 1990;27:130-132.
437. Lapunzina P. Other tumors in Sotos syndrome. Am J Med Genet A. 2005;135:228.
438. Quezada E, Gripp KW. Costello syndrome and related disorders. Curr Opin Pediatr. 2007;19:636-644.
439. Aoki Y, Niihori T, Kawame H, et al. Germline mutations in HRAS proto-oncogene cause Costello syndrome. Nat Genet. 2005;37:1038-1040.
440. Gripp KW. Tumor predisposition in Costello syndrome. Am J Med Genet C Semin Med Genet. 2005;137C:72-77.
441. DeBaun MR. Screening for cancer in children with Costello syndrome. Am J Med Genet. 2002;108:88-90.
442. Lachlan KL, Lucassen AM, Bunyan D, et al. Cowden syndrome and Bannayan Riley Ruvalcaba syndrome represent one condition with variable expression and age-related penetrance: results of a clinical study of PTEN mutation carriers. J Med Genet. 2007;44:579-585.
443. Lynch NE, Lynch SA, McMenamin J, et al. Bannayan-Riley- Ruvalcaba syndrome: a cause of extreme macrocephaly and neurodevelopmental delay. Arch Dis Child. 2009;94:553-554.
444. Ekinci S, Karnak I, Balci S, et al. Bannayan-Riley-Ruvalcaba syndrome from the point of view of the pediatric surgeon. Eur J Pediatr Surg. 2006;16:209-213.
445. Blumenthal GM, Dennis PA. PTEN hamartoma tumor syndromes. Eur J Hum Genet. 2008;16:1289-1300.
446. Gustafson S, Zbuk KM, Scacheri C, et al. Cowden syndrome. Semin Oncol. 2007;34:428-434.
447. Adlard JW. Cowden syndrome: a rare, but recognisable cancer predisposition disorder. Clin Oncol (R Coll Radiol). 2005;17:393.
448. Pilarski R. Cowden syndrome: a critical review of the clinical literature. J Genet Couns. 2009;18:13-27.
449. Lowichik A, White FV, Timmons CF, et al. Bannayan-Riley- Ruvalcaba syndrome: spectrum of intestinal pathology including juvenile polyps. Pediatr Dev Pathol. 2000;3: 155-161.
450. Gorlin RJ, Cohen MM Jr, Condon LM, et al. Bannayan- Riley-Ruvalcaba syndrome. Am J Med Genet. 1992;44: 307-314.
451. Eng C, Hampel H, De la Chapelle A. Genetic testing for cancer predisposition. Annu Rev Med. 2001;52:371-400.
452. Lynch PM. New issues in genetic counseling of hereditary colon cancer. Clin Cancer Res. 2007;13:6857s-6861s.
453. Clarke AJ, Gaff C. Challenges in the genetic testing of children for familial cancers. Arch Dis Child. 2008;93: 911-914.
454. Jarvinen HJ. Genetic testing for polyposis: practical and ethical aspects. Gut. 2003;52(suppl 2):ii19-ii22.
455. Giarelli E. Ethical issues in genetic testing. The experiences of one family diagnosed with an inherited cancer syndrome. J Infus Nurs. 2001;24:301-310.
456. Kumanyika S. Truth and confidentiality without harm. Ethics Behav. 1995;5:193-194; discussion 199-202.
457. Leikin S. First, do no harm. Ethics Behav. 1995;5:193-194; discussion 196-199.
458. De Wert G. Ethics of predictive DNA-testing for hereditary breast and ovarian cancer. Patient Educ Couns. 1998;35: 43-52.
459. Evans G. Ethical issues: the geneticist's view point. Dis Markers. 1992;10:199-203; discussion 211-228.
460. MacDonald DJ, Lessick M. Hereditary cancers in children and ethical and psychosocial implications. J Pediatr Nurs. 2000;15:217-225.